Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS...

|By:, SA News Editor

Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS outlook to reflect the $37M redemption of convertible debt the medical device company announced earlier this week as well as reduced estimates for the U.S. spine market.